Martuza
Robert Martuza, Marblehead, MA US
Patent application number | Description | Published |
---|---|---|
20110177032 | USE ON ONCOLYTIC HERPES VIRUSES FOR KILLING CANCER STEM CELLS - The invention, in some aspects, relates to the selective killing of cancer stem cells by oncolytic Herpes virus mediated oncolysis. In some aspects, the invention relates to methods for treating a subject having a cancer stem cell by administering to the subject an oncolytic Herpes virus. In other aspects, the invention provides methods for evaluating the efficacy of an oncolytic Herpes virus for killing cancer stem cells. | 07-21-2011 |
Robert L. Martuza, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110070262 | Viral Vectors and Their Use in Therapeutic Methods - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 03-24-2011 |
20130280299 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 10-24-2013 |
20150071965 | VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease. | 03-12-2015 |
Robert L. Martuza, Marblehead, MA US
Patent application number | Description | Published |
---|---|---|
20090285860 | Cancer immunotherapy - Method of stimulating an immune response (e.g., to treat cancer) include administering to a subject a composition including dendritic cells incubated with (i) oHSV-infected tumor cells or a composition derived therefrom, or (ii) tumor cells plus oHSV, as well as methods of preparing such compositions, are described. | 11-19-2009 |
Robert L. Martuza, Chevy Chase, MD US
Patent application number | Description | Published |
---|---|---|
20090053178 | USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells. According to the latter approach, both the first HSV and the second HSV may have genomes that comprise, respectively, an expressible nucleotide sequence coding for at least one immune modulator. In another embodiment, the pharmaceutical composition comprises, in addition to a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells, a viral vector comprising at least one expressible nucleotide sequence coding for at least one immune modulator. | 02-26-2009 |
Robert L. Martuza, Chavey Chase, MD US
Patent application number | Description | Published |
---|---|---|
20130224243 | USE OF HERPES VECTORS FOR TUMOR THERAPY - Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator. | 08-29-2013 |